March 08, 2026 — 82 articles reviewed
This cycle was dominated by a surge of coverage around cannabis compounds and fatty liver disease, alongside consistent warnings about adolescent psychiatric risk and promising advances in cannabinoid drug delivery. Clinicians also saw emerging signals that GLP-1 agonists may reduce substance use disorder risk, plus ongoing regulatory battles over THC potency, drug testing, and occupational access.
The science is advancing faster than the policy, and this cycle proves it: we have compelling preclinical data on liver disease, reassuring cognitive safety data in older adults, and real delivery technology breakthroughs, all while patients navigate a regulatory landscape that still punishes them for following their physician’s recommendations. Clinicians who stay current with this evidence will be the ones who can actually help their patients make informed decisions rather than guessing in the dark.
Digest-Level Clinical Commentary
Clinical Reflection
The emerging evidence linking cannabis compounds to fatty liver disease trajectories, particularly in the context of rising GLP-1 agonist use among patients with metabolic syndrome, suggests we need to refine our patient stratification protocols and drug interaction assessments in cannabis medicine practice. Given the persistent adolescent safety signals and potential metabolic interactions with increasingly prevalent obesity medications, I’m reconsidering my baseline screening approach to include liver function assessment and metabolic risk profiling before recommending cannabis therapeutics. This convergence of data points toward a more nuanced, personalized medicine framework rather than the population-level recommendations that have historically guided our field.
Clinical Perspective
Recent literature highlights a growing body of evidence examining cannabis’ metabolic effects, particularly regarding hepatic steatosis, which warrants closer monitoring in patient populations with existing metabolic risk factors. Concurrently, emerging data on GLP-1 agonists’ potential role in substance use disorder reduction represents an intriguing mechanistic avenue that may inform future prevention and treatment strategies. These trends underscore the importance of integrating cannabis exposure assessment into standard metabolic evaluations while maintaining vigilance around adolescent use given developmental considerations.
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it: